A statement from the Bionical Emas Group on guidance & measures regarding COVID-19 - read here

In relation to staff and visitor safety, we have full risk assessments in place for all of our workplaces. These risk assessments are revisited and updated regularly, to reflect changing risks, knowledge and circumstances, and to reflect evolving Government guidance. We have not placed the risk assessments here on the website as they would become out of date too quickly. However, you are welcome to email info@bionical-emas.com to request access to our most up to date risk assessments applicable to your needs. Please note that all our staff are notified of all applicable risk assessments and updates, along with ‘quick guides’ automatically via our e-learning system.

HomeResource LibraryA guide to the Development Safety Update...

Outline.

A Development Safety Update Report (DSUR) is a concise yet comprehensive analytical report, presenting the assessment of risk and any changes, in accordance with previous knowledge of the safety of the investigational drug. The DSUR is now a legal requirement in the European Union (EU) and widely accepted by Regulatory Authorities outside of the EU including the FDA and Asia Pacific. The format widely accepted is in ICH E2F.

What is the goal?.

  • To review and assess the risks and any changes since previous knowledge
  • To provide a summary of any safety issues that could have an impact on the protection of clinical study participants
  • Summarise the current understanding and management of any identified and potential safety risks to exposed patients
  • Provide an update on the status of the clinical development program and study results

When should a DSUR be submitted?.

The report should be submitted at yearly intervals from the year of the Development International Birth Date (DIBD – the date of first authorisation of a clinical trial in any country worldwide).

Have you considered?.

  • Coordination of the DSUR with the Reference Safety Information (RSI) update
  • Harmonised submissions of the PSUR and DSUR each year since there can be overlap between the content of the DSUR and PSUR
  • There should be only one DSUR for one investigational drug (active moiety), regardless of different strengths, formulations and indications

How can Bionical Emas help?.

The DSUR can be a complex document but Bionical Emas have extensive expertise in house with 15+ years’ experience in writing these aggregate reports, covering all elements of DSUR and other safety document development such as line listings.

Bionical Emas can provide a consolidated safety reporting system, together with the in-house expertise to produce an accurate report for the Regulatory Authorities and Regional Ethics Committees. Bionical Emas can produce DSURs as standalone projects, as well as part of a pharmacovigilance service for full service clinical trial programmes.

Why use Bionical Emas?.

Having produced over 70 DSUR’s/Annual Reports, all submitted on time and accurately, clients can be sure that their study DSURs are in safe hands with Bionical Emas.

How can we support you?

Our dedicated teams of experts are on hand to help should you require any additional resource or further information about our services.